AURORA, CO, OncoVerity, a pioneer in applying advanced bioinformatics to drug development, announced the closing of a Series A extension financing led by existing investors, argenx and RefinedScience.
OncoVerity, a pioneer in applying advanced bioinformatics to drug development, announced the closing of a Series A extension financing led by existing investors, argenx and RefinedScience. With this funding, OncoVerity aims to advance its mission to address the unmet medical need of cancer patients, leveraging a unique computational approach to inform a development strategy that seeks breadth and depth of response.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
